-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[China Pharmaceutical network industry trends] recently, the "slimming campaign" of layoffs in all walks of life has stirred many people's nerves In the pharmaceutical industry, there are also a number of large-scale layoffs It can be said that the tide of layoffs is rolling forward, and every medical person is a little scared Novo Nordisk cut 400 jobs On September 18, Novo Nordisk's website released a plan to change its research and development mode, announcing 400 job cuts in China and Denmark as part of the restructuring of its research and development department It is reported that the move will affect 30 employees of China R & D center As early as June this year, the media reported that Novo Nordisk is considering implementing cost reduction plans, or will significantly cut about 3000 people It is reported that Novo Nordisk's downsizing and restructuring aims to "accelerate the expansion and diversification of its pipeline for serious chronic diseases", and increase investment in transformation biology and technological innovation in core treatment areas and new treatment areas Novo Nordisk hopes to successfully develop a series of chronic disease drugs by streamlining the team's focus, so as to share and reduce the market pressure faced by its core diabetes business In addition, Novo Nordisk said it is expected to set up four "transformation research units" by the end of 2018 focusing on finding new therapies and technologies At the same time, the company will invest in automation, machine learning and artificial intelligence Integrate laboratory infrastructure and information technology systems to improve the efficiency of R & D institutions GSK cut 650 jobs on September 12, GlaxoSmithKline (GSK), a British pharmaceutical company, announced that it would cut 650 jobs in the United States, including 200 in-house staff and 450 pharmaceutical representative positions At the same time, GSK's layoff project has been reported to the U.S Department of Commerce and the States The capital surplus from layoffs will be invested in the research and development of new products and business support It is reported that GSK's move is mainly to optimize the supply chain and reduce administrative costs, significantly improving the competitiveness and efficiency of the group, and directly saving more than $500 million annually Takeda closed 1000 jobs Takeda announced on September 11 its plan to close its U.S headquarters in the Chicago area and focus its U.S business in the Boston area where shire operates, which will close 1000 related jobs and promise to cut about 7% of its combined employees According to the industry, behind the large-scale layoff plans of these pharmaceutical companies, there are also survival difficulties that many multinational pharmaceutical companies need to break at present On the one hand, the market advantages of these pharmaceutical companies will be gradually covered by generic drugs when many heavy drug protections expire; on the other hand, due to the heavy investment in new drug research and development, little effect will be achieved In addition, the high cost of research and development, the long time cycle, and the sales of new drugs are not as many obstacles as before It is natural for pharmaceutical companies to reduce personnel expenditure It can be predicted that the cold wave of layoffs in the pharmaceutical industry is approaching
In my opinion, at present, the consistency evaluation of generic drugs is in full swing in China With the continuous change of the pharmaceutical market environment, the business model of pharmaceutical enterprises is facing transformation, and the structural reform to improve business efficiency and reduce the number of employees becomes an urgent task The survival of the fittest is also a normal trend for most pharmaceutical companies... but in the current increasingly tightening of the medical industry, how to improve self The irreplaceable nature of the body and the avoidance of "layoffs" are issues that many medical professionals need to think about in the near future.